Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Harry Masuda | M | 79 |
Human BioSystems, Inc.
 Human BioSystems, Inc. Miscellaneous Commercial ServicesCommercial Services The Company's principal activity is to develop and provide economical, non-toxic methods of extending the shelf life and improving the quality of blood platelets and other biological material. The customers include blood banks, hospitals, clinics and similar organizations. The primary competitors include DuPont, Baxter, LifeCell, Cerus and Cryo Life. It is currently in the developmental stage. | - |
| George Tsukuda | M | - |
Human BioSystems, Inc.
Human BioSystems, Inc. Miscellaneous Commercial ServicesCommercial Services The Company's principal activity is to develop and provide economical, non-toxic methods of extending the shelf life and improving the quality of blood platelets and other biological material. The customers include blood banks, hospitals, clinics and similar organizations. The primary competitors include DuPont, Baxter, LifeCell, Cerus and Cryo Life. It is currently in the developmental stage. | - |
| Larry McCleary | M | 73 |
Human BioSystems, Inc.
Human BioSystems, Inc. Miscellaneous Commercial ServicesCommercial Services The Company's principal activity is to develop and provide economical, non-toxic methods of extending the shelf life and improving the quality of blood platelets and other biological material. The customers include blood banks, hospitals, clinics and similar organizations. The primary competitors include DuPont, Baxter, LifeCell, Cerus and Cryo Life. It is currently in the developmental stage. | 4 years |
| Robert E. Strom | M | - |
Human BioSystems, Inc.
Human BioSystems, Inc. Miscellaneous Commercial ServicesCommercial Services The Company's principal activity is to develop and provide economical, non-toxic methods of extending the shelf life and improving the quality of blood platelets and other biological material. The customers include blood banks, hospitals, clinics and similar organizations. The primary competitors include DuPont, Baxter, LifeCell, Cerus and Cryo Life. It is currently in the developmental stage. | - |
| Luis H. Toledo-Pereyra | M | 79 |
Human BioSystems, Inc.
Human BioSystems, Inc. Miscellaneous Commercial ServicesCommercial Services The Company's principal activity is to develop and provide economical, non-toxic methods of extending the shelf life and improving the quality of blood platelets and other biological material. The customers include blood banks, hospitals, clinics and similar organizations. The primary competitors include DuPont, Baxter, LifeCell, Cerus and Cryo Life. It is currently in the developmental stage. | 9 years |
| Rachmat M. Umar | M | - |
Human BioSystems, Inc.
Human BioSystems, Inc. Miscellaneous Commercial ServicesCommercial Services The Company's principal activity is to develop and provide economical, non-toxic methods of extending the shelf life and improving the quality of blood platelets and other biological material. The customers include blood banks, hospitals, clinics and similar organizations. The primary competitors include DuPont, Baxter, LifeCell, Cerus and Cryo Life. It is currently in the developmental stage. | - |
| David Winter | M | 89 |
Human BioSystems, Inc.
Human BioSystems, Inc. Miscellaneous Commercial ServicesCommercial Services The Company's principal activity is to develop and provide economical, non-toxic methods of extending the shelf life and improving the quality of blood platelets and other biological material. The customers include blood banks, hospitals, clinics and similar organizations. The primary competitors include DuPont, Baxter, LifeCell, Cerus and Cryo Life. It is currently in the developmental stage. | 4 years |
| Frank J. Drechsler | M | 57 |
Human BioSystems, Inc.
Human BioSystems, Inc. Miscellaneous Commercial ServicesCommercial Services The Company's principal activity is to develop and provide economical, non-toxic methods of extending the shelf life and improving the quality of blood platelets and other biological material. The customers include blood banks, hospitals, clinics and similar organizations. The primary competitors include DuPont, Baxter, LifeCell, Cerus and Cryo Life. It is currently in the developmental stage. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 8 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Paul Okimoto
- Personal Network
